BioGaia AB (publ) (LON:0GTN)
London · Delayed Price · Currency is GBP · Price in SEK | Market Cap | 1.05B +32.1% |
| Revenue (ttm) | 122.90M +8.8% |
| Net Income | 26.42M +7.2% |
| EPS | 0.26 +7.3% |
| Shares Out | n/a |
| PE Ratio | 39.83 |
| Forward PE | 29.90 |
| Dividend | 0.32 (0.26%) |
| Ex-Dividend Date | May 8, 2026 |
| Volume | 8,268 |
| Average Volume | 12,549 |
| Open | 130.15 |
| Previous Close | 130.00 |
| Day's Range | 130.15 - 130.90 |
| 52-Week Range | 93.60 - 130.90 |
| Beta | 0.31 |
| RSI | 71.88 |
| Earnings Date | May 7, 2026 |
About BioGaia AB
BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula and milk formula. Its Adult Health segment provides gut health tablets, bone health tablet... [Read more]
Financial Performance
In 2025, BioGaia AB's revenue was 1.54 billion, an increase of 8.11% compared to the previous year's 1.42 billion. Earnings were 332.76 million, a decrease of -5.30%.
Financial numbers in SEK Financial StatementsNews
BioGaia AB Earnings Call Transcript: Q1 2026
Organic growth reached 15% year-over-year, driven by strong direct market performance and new product launches. EBIT margin remained at 27%, with double-digit growth in both pediatric and adult segments. Currency effects weighed on reported growth and gross margin.
BioGaia AB Earnings Call Transcript: Q4 2025
Q4 organic sales grew 32% and full-year 2025 organic growth reached 14%, with strong gains in direct markets and new product launches. EBIT margin was 27% for Q4, and a total dividend of SEK 4 per share is proposed.
BioGaia AB Earnings Call Transcript: Q3 2025
Q3 saw 7% sales growth (14% organic), with strong gains in the Americas and Asia Pacific, and direct markets now 36% of sales. EBIT margin rose to 26%, driven by improved mix and price, while new product launches and direct market expansion are set to fuel future growth.
BioGaia AB Earnings Call Transcript: Q2 2025
Q2 sales grew 5% to SEK 405 million, with strong organic growth in the Americas and Asia Pacific, but EBIT fell 20% due to higher marketing and expansion costs. Direct sales and new product launches drove growth, while cash flow and margins were impacted by increased investments.
BioGaia AB Earnings Call Transcript: Q1 2025
Q1 2025 sales were flat at SEK 366 million, with EBIT down 32% due to higher costs and currency effects. Americas grew 42% while EMEA and Asia-Pacific declined; direct sales initiatives in France and the Netherlands are expected to drive growth in the second half.
BioGaia AB Earnings Call Transcript: Q4 2024
Q4 sales rose 23% to 365 million SEK, with EBIT up 28% and strong growth in the Americas and EMEA. Gross margin declined due to a one-time U.S. inventory write-down, but adjusted EBIT margin for the year was 34%. Dividend of 6.90 SEK per share proposed.
BioGaia AB Earnings Call Transcript: Q3 2024
Q3 saw a 4% sales decline, mainly from EMEA, while Asia Pacific and Americas grew. EBIT dropped 65% due to a SEK 51.2 million impairment, but adjusted EBIT margin was 31%. Direct markets and new product launches are driving future growth, with strong momentum in Asia and the U.S.
BioGaia AB Earnings Call Transcript: Q2 2024
Q2 sales rose 22% to SEK 384 million, with EBIT up 42% and strong growth in Asia-Pacific and Americas. Strategic investments in marketing, R&D, and direct markets are expected to drive future growth, though short-term margins may be impacted.